2018年版Drugs to Watchで取り上げた将来のブロックバスター候補の中でも、Gilead社のBiktarvyが米国・欧州市場で成功を収めています。 この先もBiktarvyの躍進は続くのか?拡大するHIV市場と、その中でしのぎを削る競合品をレビューしました。   From gene therapies and vaccines, to combination therapies and antibodies, treatments in the Cortellis Drugs to Watch 2018 report were varied both in action and target. The Cortellis team featured 12 potential blockbusters last year which had forecasted sales of more than $1 billion by 2022.  One treatment stood out, due to […]